Trial Profile

CD19-targeted CAR T Cells JWCAR029 for Primary Refractory Diffuse Large B Cell Lymphoma, Phase Ⅰ,Open-label,Single-arm,Muticenter Study

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Relmacabtagene-autoleucel (Primary)
Indications Diffuse large B cell lymphoma
Focus Adverse reactions

Most Recent Events

21 Nov 2023 Status changed from recruiting to completed.
07 Jun 2022 Preliminary results (n=12; as of 24 Nov 2021) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
05 Jun 2022 According to a JW Therapeutics media release, preliminary results from this study presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com